Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma

Trial Profile

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AUGMENT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Dec 2018 Results presented in a Celgene Corporation Media Release.
    • 02 Dec 2018 According to a Celgene Corporation media release, data from the study were presented at the 2018 American Society of Hematology (ASH) annual meeting.
    • 25 Oct 2018 According to a Celgene Corporation media release, data from the study will be presented at the 2018 American Society of Hematology (ASH) annual meeting in December.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top